Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Jul 2004a;80(1):76-81
PEER REVIEW The peer review history for this article is available at Supporting information ACKNOWLEDGEMENTS The authors would also like to acknowledge Caroline Spencer (Rx Communications, Mould, UK) for medical writing assistance with the preparation of this manuscript, funded by Eli Lilly and Company
Likewise, among patients with COPD, nasopharyngeal acquisition of a new NTHi strain is frequently associated with the onset of an acute exacerbation (Sethi et al., 2002)
Protect from direct heat and light
The Journal of clinical endocrinology and metabolism, 108(1), 412
Effective patent life the period between commercial launch and first generic or biosimilar entry averages 7-12 years
US$ 21.47
US$ 27.29
US$ 21.37
